# A Study of the Safety and Efficacy of Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Methotrexate

> **NCT00243412** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 42 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** folate
- **DRUG:** methotrexate
- **DRUG:** methylprednisolone
- **DRUG:** Placebo
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00243412
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2011-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00243412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00243412, "A Study of the Safety and Efficacy of Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Methotrexate". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00243412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*